{
    "nctId": "NCT06272799",
    "briefTitle": "Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents.",
    "officialTitle": "Tolerability and Efficacy of Adjuvant T-DM1 in Patients with HER2 Positive Breast Cancer After Incomplete Pathological Response to Neoadjuvant Chemotherapy Including Anti-HER2 Agents. Real-world Multicenter Retrospective-prospective Study. ATD-Study.",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 160,
    "primaryOutcomeMeasure": "Evaluate the tolerability.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological diagnosis of HER2 positive breast cancer;\n* Presence of invasive residual disease on T or N after neoadjuvant chemotherapy including anti-HER2 agents\n* Treatment with T-DM1 in the adjuvant post-neoadjuvant setting, in case of positive hormone receptors in combination with adjuvant hormone therapy. Complementary radiotherapy will be allowed as per lines guide;\n* Availability of adequate information regarding treatment with adjuvant T-DM1 in accordance with the objectives of the study;\n* Written informed consent for the prospective part and, if possible, for the recruited patients retrospectively\n\nExclusion Criteria:\n\n* Concomitant treatments with other biological agents;\n* Absence of clinical data that allow the correct analysis of the primary and secondary objectives;\n* Patients with a history of other malignant neoplasms;\n* Contraindications to the use of T-DM",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}